Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC34A2 | O95436 | 11/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | LCK | P06239 | 1/20 | 0.35 |
| ▸ | TEK | Q02763 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | RAF1 | P04049 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL40435 | 1.00 | SLC34A2 (0.40) | SLC34A2GFERALDH1A1KDM4EMAPT | |
| SCHEMBL44753 | 0.91 | SLC34A2 (0.40) | SLC34A2GFERALDH1A1KDM4EMAPT | |
| SCHEMBL44752 | 0.91 | SLC34A2 (0.40) | SLC34A2GFERALDH1A1KDM4EMAPT | |
| SCHEMBL45187 | 0.91 | SLC34A2 (0.42) | SLC34A2KDM4EMAPTMEN1KMT2A | |
| SCHEMBL46929 | 0.91 | SLC34A2 (0.42) | SLC34A2KDM4EMAPTMEN1KMT2A | |
| SCHEMBL10274451 | 0.90 | SLC34A2 (0.43) | SLC34A2ALDH1A1MAPTLCKTEK | |
| SCHEMBL46633 | 0.89 | SLC34A2 (0.41) | SLC34A2LCKTEKRAF1 | |
| SCHEMBL15421050 | 0.89 | SLC34A2 (0.41) | SLC34A2LCKTEKRAF1 | |
| SCHEMBL46942 | 0.88 | SLC34A2 (0.42) | SLC34A2ALDH1A1MAPTLCKTEK | |
| SCHEMBL15421036 | 0.88 | SLC34A2 (0.42) | SLC34A2ALDH1A1MAPTLCKTEK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2591354-B1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX INC (US) | 2016-09-07 | — | — | EP | disclosed |
| US-20140023611-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. | 2014-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140023611-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | SLC10A2, SLC34A2, SLC34A3 | SLC34A2 2/4885GFER 3759/4885ALDH1A1 3332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.